A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

Breast Neoplasms Clinical Trial

Official title:

Escalation Study of BTP-114 in Patients With Advanced Solid Tumors and BRCA or DNA Repair Mutation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02950064
• Other study ID #: BTP-114-001
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: September 2016
• Est. completion date: August 2020

Study information

• Verified date: January 2019
• Source: Placon Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1, Open-label, multicenter Dose Escalation study of BTP-114, a novel platinum product, in patients with advanced solid tumors and BRCA or other DNA repair mutation. This clinical study is comprised of 2 sequential parts: Part 1 (Dose Escalation) and Part 2 (Expansion). The purpose of this study is to evaluate the safety, pharmacokinetics and the anti-cancer activity of BTP-114.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 95
• Est. completion date: August 2020
• Est. primary completion date: April 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

INCLUSION:

All Patients

1. Male or female aged =18 years.

2. ECOG PS score of 0-1.

3. Adequate organ function.

4. Ability to understand and willingness to sign informed consent form prior to initiation of study procedures.

5. Measurable disease per RECIST, OR for patients with a primary diagnosis of castration resistant prostate cancer, progressive disease (PD) by prostate surface antigen (PSA) or imaging in the setting of medical or surgical castration.

6. Documented BRCA mutation, with the following exceptions: a) Patient is intended to be enrolled in a Single-patient Cohort; b) Patient has an advanced DNA repair mutation-positive solid tumor and is intended to be enrolled in Expansion Cohort 5.

Patients in the Dose-escalation Phase:

7. Locally advanced solid tumor other than a primary central nervous system (CNS) tumor for which the patient has received =3 prior lines

8. Confirmed solid tumor in one of the following categories:

• BRCA mutation-positive pancreatic cancer for which the patient received up to 1 prior line of cytotoxic chemotherapy in the advanced disease setting.

• Advanced BRCA mutation-positive castration-resistant prostate cancer (CRPC) for which the patient received up to 2 prior lines of cytotoxic chemotherapy in the advanced disease setting.

• Advanced BRCA mutation-positive ovarian cancer for which the patient received up to 3 prior lines of cytotoxic chemotherapy in the advanced disease setting.

• Advanced BRCA mutation-positive triple-negative breast cancer (TNBC) for which the patient received up to 3 prior lines of cytotoxic chemotherapy in the advanced disease setting.

• Advanced DNA repair mutation-positive solid tumors, including, but not limited to BRCA and non-BRCA DNA mutations, who have received up to 3 prior lines of cytotoxic chemotherapy in the advanced disease setting. DNA-repair mutations may include, but are not limited to ATM, CHEK2, PALB2, and RAD51D. Abnormal homologous repair deficiency (HRD) tests will also be allowed.

Note that in both dose escalation and dose expansion portions of the study, prior targeted therapy including prior poly ADP ribose polymerase (PARP) inhibitor therapy, prior immunotherapy, or prior hormonal therapy is permissible. Patients with castration resistant prostate cancer may have received unlimited prior hormonal therapies.

EXCLUSION:

1. History of leptomeningeal disease or spinal cord compression.

2. Underwent major surgery within 4 weeks before first treatment.

3. Received cancer-directed therapy 14 days (6 weeks for mitomycin C and nitrosoureas) before start of treatment.

4. Grade 2 or greater peripheral neuropathy at start of treatment.

5. If female, pregnant or breast-feeding.

6. Known human immunodeficiency virus (HIV) infection or hepatitis B or C infection

7. Any primary brain tumor (e.g., astrocytoma, glioblastoma).

8. Hypersensitivity or history of anaphylactic reaction to any platinum-containing agents.

Related Conditions & MeSH terms

• Breast Neoplasms
• Neoplasms
• Ovarian Neoplasms
• Pancreatic Neoplasms
• Prostatic Neoplasms

Intervention

Drug:
• BTP-114
Part 1 (Escalation) IV treatment of BTP-114 in 21-day cycles. Doses will be increased in sequential cohorts until the maximum tolerated dose is determined which will lead to the recommended phase 2 dose Part 2 (Expansion) 5 cohorts of patients will be treated at the RP2D of IV BTP-114 in 21-day cycles for the tumor types pancreatic cancer, castration-resistant prostate cancer, ovarian cancer, triple-negative breast cancer and deoxyribonucleic acid (DNA) repair mutation-positive advanced solid tumors.

Locations

Country	Name	City	State
United States	Placon Therapeutics Clinical Trial Site	Boston	Massachusetts
United States	Placon Therapeutics Clinical Trial Site	Boston	Massachusetts
United States	Placon Therapeutics Clinical Trial Site	Cleveland	Ohio
United States	Placon Therapeutics Clinical Trial Site	Houston	Texas
United States	Placon Therapeutics Clinical Trial Site	Nashville	Tennessee
United States	Placon Therapeutics Clinical Trial Site	Oklahoma City	Oklahoma
United States	Placon Therapeutics Clinical Trial Site	Saint Louis	Missouri
United States	Placon Therapeutics Clinical Trial Site	Sarasota	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Placon Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Part 1 - Proportion of patients with an objective response (ORR) using the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 or the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria.		From the date of the first dose to documented disease progression assessed up to approximately 52 weeks.
Other	Part 1 - Proportion of patients whose disease is controlled (DCR) using RECIST, Version 1.1 or PCWG2 criteria.		From the date of the first dose to documented disease progression assessed up to approximately 52 weeks.
Other	Part 1 - Duration of response (DOR) measured from the date of first CR or PR until the first date of progressive disease or death from any cause.		Assessed up to approximately 52 weeks.
Other	Part 1 - Progression-free survival (PFS) measured as the time from the date of initiation of BTP-114 treatment to the documented disease progression (PD) or death from any cause.		Assessed up to approximately 52 weeks.
Other	Part 1 - Plasma Pharmacokinetics (PK) estimates of platinum concentration, Area under plasma Concentration (AUC) 0 to t.		Time points on Day 1, Day 3 or Day 4, Day 15 of Cycle 1 and Day 1 of subsequent cycles.
Other	Part 1 - Plasma Pharmacokinetics (PK) estimates of platinum concentration, time of Maximum concentration (Tmax).		Time points on Day 1, Day 3 or Day 4, Day 15 of Cycle 1 and Day 1 of subsequent cycles.
Other	Part 1 - Plasma Pharmacokinetics (PK) estimates of platinum concentration Half-life (T1/2).		Time points on Day 1, Day 3 or Day 4, Day 15 of Cycle 1 and Day 1 of subsequent cycles
Primary	Part 1 - Maximum tolerated dose (MTD) of BTP-114 determined during the dose escalation phase of study based on number of patients experiencing a dose-limiting toxicity.		From the date of the first dose up to approximately 52 weeks.
Primary	Part 1 - Recommended Phase 2 Dose (RP2D) of BTP-114 based on the MTD, review of adverse event data and review of AUC, Tmax and t1/2 obtained from PK data during the dose escalation phase of the study.		From the date of the first dose up to approximately 52 weeks.
Primary	Part 1 - Number of patients experiencing treatment-related adverse events as assessed by CTCAE v4.3 during the study.		From the date of first dose up to approximately 52 weeks.
Primary	Part 2 - Proportion of patients with an objective response (ORR) using the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 or the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria.		From the date of the first dose to documented disease progression assessed up to approximately 52 weeks.
Primary	Part 2 - Proportion of patients whose disease is controlled (DCR) using RECIST, Version 1.1 or PCWG2 criteria.		From the date of the first dose to documented disease progression assessed up to approximately 52 weeks.
Primary	Part 2 - Duration of response (DOR) measured from the date of first CR or PR until the first date of progressive disease or death from any cause.		Assessed up to approximately 52 weeks.
Primary	Part 2 - Progression-free survival (PFS) measured as the time from the date of initiation of BTP-114 treatment to the documented disease progression (PD) or death from any cause.		Assessed up to approximately 52 weeks.